Effect of Olive Pomace Oil on Blood Sugar Levels
Assessment of the Potential Antidiabetic Effects of Olive Pomace Oil in Diabetic or Prediabetic Subjects: Postprandial Study and Chronic Intervention
This study is testing if adding olive pomace oil to meals can help people with type 2 diabetes or those at risk manage their blood sugar levels better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 20 Years to 70 Years |
| Sex | All |
| Sponsor | Instituto de Ciencia y Tecnología de Alimentos y Nutrición Government |
| Locations | 1 site (Madrid, Madrid) |
| Trial ID | NCT06723886 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the potential benefits of olive pomace oil in managing blood glucose levels in individuals with type 2 diabetes and those at risk of developing the disease. Participants will consume meals with either olive pomace oil or a comparison oil, and their blood glucose responses will be measured. The study includes both a postprandial phase, where immediate blood sugar responses are assessed, and a chronic phase, where the long-term effects of daily olive pomace oil consumption are evaluated. The goal is to determine if olive pomace oil can improve glucose homeostasis and reduce inflammation in these patients.
Who should consider this trial
Good fit: Ideal candidates include individuals with fasting blood glucose levels between 100-126 mg/dL or those diagnosed with type 2 diabetes.
Not a fit: Patients with kidney or liver diseases, gastrointestinal disorders, or those on certain medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a dietary intervention to help manage blood sugar levels in patients with diabetes or prediabetes.
How similar studies have performed: Other studies have shown promising results with dietary interventions for diabetes management, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Fasting blood glucose between 100-126 mg/dL and/or * Glycated haemoglobin (HbA1c) between 5.7-6.4% and/or * Diabetic persons with Fasting blood glucose \>126 mg/dL and/or * Diabetic persons with Glycated haemoglobin (HbA1c) \> 6.4% Exclusion Criteria: * Kidney or liver diseases * Gastrointestinal diseases (irritable bowel syndrome, Crohn disease, chronic bowel inflammation) * Food allergies/intolerances * Vegetarians/vegans * Smoking * Pregnant or lactating women * On prescription drugs other than for hypertension/thyroid/dyslipidemia/glucose control, or changes in dosage in the last 3 months * Consumption of vitamins, dietary supplements or nutraceuticals
Where this trial is running
Madrid, Madrid
- Institute of Food Science, Technology and Nutrition (ICTAN-CSIC) — Madrid, Madrid, Spain (Recruiting)
Study contacts
- Principal investigator: Laura Bravo, Professor — Ictan-Csic
- Study coordinator: Laura Bravo, Professor
- Email: lbravo@ictan.csic.es
- Phone: +34 91 5492300
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.